Anti-Hypertensive Drugs - Nepal

Nepal

The Anti-Hypertensive Drugs market in Nepal is projected to reach a revenue of NPR US$3.63m in 2024.
It is expected to exhibit an annual growth rate of 0.76% (CAGR 2024-2029), resulting in a market volume of NPR US$3.77m by 2029.
In a global comparison, United States is anticipated to generate the highest revenue of US$12,290.00m in 2024.
Nepal's anti-hypertensive drug market is witnessing a surge in demand due to the increasing prevalence of hypertension among its population.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Nepal has been experiencing significant growth in recent years.

Customer preferences: There has been an increase in the incidence of hypertension in Nepal due to lifestyle changes and an aging population, leading to a higher demand for anti-hypertensive drugs. Patients in Nepal prefer affordable and easily accessible drugs, which has led to the popularity of generic drugs.

Trends in the market: The Nepalese government has been taking steps to increase access to healthcare, including the provision of free drugs for hypertension in government hospitals. This has led to an increase in demand for anti-hypertensive drugs in the market. The market is dominated by generic drugs due to their affordability and accessibility. There has also been a trend towards combination drugs, which are more convenient for patients to take.

Local special circumstances: Nepal is a developing country with a low GDP per capita, which has led to a focus on affordable healthcare. The government has been working to increase access to healthcare, including the provision of free drugs for hypertension in government hospitals. However, there is still a lack of access to healthcare in rural areas, which has led to a disparity in healthcare outcomes between urban and rural areas.

Underlying macroeconomic factors: The Nepalese economy has been growing steadily in recent years, which has led to an increase in healthcare spending. However, healthcare spending as a percentage of GDP is still low compared to other countries in the region. The government has been working to increase healthcare spending, but there are still challenges in terms of funding and infrastructure. The pharmaceutical industry in Nepal is still in its early stages of development, which has led to a reliance on imports for many drugs. This has led to challenges in terms of affordability and accessibility for some drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.